AC
MBRX icon

Armistice Capital’s Moleculin Biotech MBRX Stock Holding History

Armistice Capital’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,000
Closed -$1.22M – 242
2025
Q1 		$1.22M Buy
50,000
+37,297
+294% +$1.25M 0.02% 159
2024
Q4 		$540K Buy
12,703
+1,103
+10% +$66.8K 0.01% 177
2024
Q3 		$824K Buy
11,600
+5,360
+86% +$386K 0.01% 176
2024
Q2 		$549K Buy
6,240
+300
+5% +$34.6K 0.01% 176
2024
Q1 		$878K Sell
5,940
-2,613
-31% -$557K 0.01% 169
2023
Q4 		$2.75M Buy
+8,553
New +$1.78M 0.04% 142
2019
Q2 		– Sell
-98
Closed -$179K – 73
2019
Q1 		$179K Buy
+98
New +$292K 0.01% 69

Other funds holding MBRX

Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Armistice Capital's MBRX Position: Q2 2025 in Review

Armistice Capital sold out of Moleculin Biotech (MBRX) in Q2 2025, closing a stake of 50,000 shares — an estimated $1.22M sold.

Armistice Capital first reported a position in MBRX in Q1 2019 and held it in 7 quarters. The position peaked at $2.75M in Q4 2023. 21 funds tracked by Wall St. Rank hold MBRX as of Q2 2025.

  • Armistice Capital reported no remaining Moleculin Biotech position as of Q2 2025 after selling out during the quarter.
  • Armistice Capital sold 50,000 Moleculin Biotech shares in Q2 2025, an estimated $1.22M.
  • Armistice Capital first reported a position in Moleculin Biotech in Q1 2019 and held it in 7 quarters.
  • Armistice Capital's Moleculin Biotech position peaked at $2.75M in Q4 2023.
  • 21 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2025.

Based on Armistice Capital's 13F filing for Q2 2025, filed 14 Aug 2025.